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In 1994, the Italian group with the CD34 cell selection equipment, demonstrated decreased risk of rejection using high doses of cells ("mega dose": 13.8 x 10 6 CD34 with 1x10 4 CD3). 2 The initiatives of Chinese researchers with stringent conditioning have shown excellent results since 2006 . 3 In 2007, the Duke University group led by Nelson Chao presented a protocol without selection of CD34+ cells in vitro and in vivo depletion using Campath (alemtuzumab) in the conditioning regimen. 4 However, a major breakthrough occurred in 2008 when the group of Baltimore, led by Ephraim Fuchs, consolidated the use of cyclophosphamide on days +3 and +4 post-transplantation, also with depletion of T cells in vivo. 5 The authors published results using this type of regimen in several types of malignant diseases, such acute myeloid leukemia, acute lymphoblastic leukemia, myelodysplasia and non-Hodgkin and Hodgkin's lymphoma, with an overall survival >50% in Hodgkin's lymphoma, reaching 76%. 5 From that point onward, what we saw was a constant search for methodologies that would further improve the results of haploidentical transplants. [5] [6] [7] The advantages of using this type of transplant is the immediate donor availability, instant access to the donor for cell therapy after transplantation and the possibility of selecting several family members according to clinical characteristics and alloreactivity of NK (natural killer) cells. As disadvantages, we can mention the higher potential risk of GVHD, the need for depletion of T cells in vivo or ex vivo, leading to a higher incidence of infection due to the slow immuno-reconstitution and high incidence of recurrence. 6, 7 But undoubtedly, the great advantage is that, considering that 40-50% of patients have no related or unrelated compatible donors, HLA "mismatch" or haploidentical transplants of first-degree relatives can be found in over 95% of patients. [7] [8] [9] In Brazil, the use of post-transplantation cyclophosphamide is the one most often used to perform haploidentical transplants. This choice is not made by chance. First, it results from the high cost of processing, which is restricted to a few treatment centers that have specific protocols to be used in, for instance, congenital immunodeficiencies. Secondly, literature reports indicate that the results tend to be better, since only alloreactive lymphocytes are affected. 5, 8, 9, 10 Initial studies seeking to compare the haploidentical transplantation with other alternatives, such the umbilical cord or unrelated mismatch transplants, have not shown great superiority between one form or another of transplanting. Given that factors such as mismatch, presence of anti-HLA antibodies, KIR reactivity, NIMA and HLA C in umbilical cord can help in the decision-making, Table 1 has been widely used as a guide. [11] [12] [13] [14] [15] Recently, the MD Anderson group, led by Dr. Stefan Ciurea, showed comparable results between haploidentical and unrelated transplants, even fully compatible. This fact opens the possibility of using the haploidentical transplant primarily when compatible related donor cannot be found and when it takes longer to find unrelated donors due to genetic or operational difficulties. This finding, which has been demonstrated by other groups, will obviously change -if confirmed by clinical studies -the way we choose the best donor for hematopoietic cell transplantation, significantly modifying Table 1 and establishing the haploidentical transplant option or unrelated transplant as fully compatible for most clinical situations 16, 17 .
advantages and disadvantages of using haPloidentical donors Compared to other sources of donors, the main advantages of using haploidentical transplants are: 6, 7, 9 a) Availability: it is estimated that a patient has 2.7 potential haploidentical donors among their firstdegree relatives. This number is compared to a 25 to 30% chance of an HLA-identical family donor and the variable chances between 16% and 75% of a fully compatible donor (8 x 8) in a donor registry, depending on the genetic difficulty of each case. b) Immediate availability: in urgent cases, when compatible family donors cannot be found, a haploidentical donor will be selected quickly, compared with the mean time for search and confirmation of an unrelated donor, which is around three to four months. However, the use of methods that target T-cell depletion decreases the incidence of GVHD, but increases the risk of rejection, infection and reduces graft-versus-leukemia reaction.
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Main current strategies for haPloidentical transPlants a) In vitro T-cell depletion: This methodology employs megadoses of CD34 and is used by the Perugia group.
1,2,12,13 b) GIAC: uses G-CSF (G) granulocyte colony stimulating factor to stimulate the donor and extensive post-transplantation immunosuppression (I), using ATG (A) (antithymocyte globulin) and the combined use (C) of bone marrow and peripheral blood. This methodology is used almost exclusively in China, where there is extensive experience in haploidentical transplants. 13 c) Post-transplantation cyclophosphamide: this is the main form of T-cell depletion used worldwide, with adaptations to the first works with non-myeloablative transplants using fludarabine, low-dose (200 Gy) total body irradiation and cyclophosphamide. Cyclophosphamide 50 mg/kg is used on days +3 and +4 and the prophylaxis of graft-versus-host disease is made with MMF and tacrolimus. 4, 16, 18 d) Choice of the best donor: According to a study published by the Chinese group, the best donor is young and male. 19 The father has precedence over the mother. It is also important to assess the blood group, perform serology for cytomegalovirus, assess the presence of HLA donor-specific antibodies, NIMA (non-inherited maternal antigens) and KIR reactivity. 20 These data have not been reproduced by others and we do not know whether their use is valid for other conditioning regimens. The most important factor in all the works and for any type of methodology, is the assessment of the presence of anti-donor specific antibodies.
Brazilian exPerience with haPloidentical transPlantation
The number of haploidentical transplants have been increasing in Brazilian centers. Until mid-2013, 85 transplants had been performed. From that date until mid-2015, over 100 transplants were performed, totaling 185 cases and this number is increasing. 21 Most were performed in cases of acute leukemia (90 patients), severe aplastic anemia (24 patients) and Hodgkin's lymphoma (20 patients), with the remaining patients scattered among other indications of malignant and nonmalignant diseases. The overall survival of these patients can be seen in Graph 1. The presence of hepatic veno-occlusive disease was the only factor that had an impact on survival in the multivariate analysis of Brazilian cases as shown in Table 1 . 21 Regarding specific initiatives, the Brazilian group published a series of severe aplastic anemia cases ( Figure 3 ) at the Congress of the Brazilian Association of Hematology (ABHH) in 2015. 22, 23 The main initiatives in haploidentical transplants of the Brazilian Society of Bone Marrow Transplantation (SBTMO) were established at the society meetings, with members interested in the area and the creation of uniform protocols for the following situations: acute myeloid leukemia and myelodysplasia, acute lymphocytic leukemia, Hodgkin's lymphoma and severe aplastic anemia.
conclusion
The haploidentical transplantation is a type of procedure that has become more and more popular among specialists in the area. The use of post-transplant cyclophosphamide has popularized its use. In some pathologies, the results are as good as in related and unrelated transplants. In Brazil, its use has gained much acceptance. 
